健帆生物(300529.SZ):一次性使用血液灌流器取得醫療器械註冊證
格隆匯12月16日丨健帆生物(300529.SZ)公佈,公司於近日收到國家藥品監督管理局頒發的《醫療器械註冊證》,產品名稱:一次性使用血液灌流器;註冊證有效期:2019年12月4日至2024年12月3日;臨牀用途:用於維持期血液透析患者進行血液灌流治療,清除以β2微球蛋白(β2-MG)為代表的尿毒症中大分子毒素。
這一新產品註冊證的取得,進一步滿足了尿毒症治療的臨牀需求,符合公司“專病專灌”的產品戰略,提升了公司的核心競爭力,將對公司未來的經營發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.